Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

@article{Heier2006RanibizumabCW,
  title={Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.},
  author={Jeffrey S. Heier and David S Boyer and Thomas A. Ciulla and Philip J. Ferrone and James Michael Jumper and Ronald C. Gentile and Debbi Kotlovker and Carol Y Chung and Robert YoungChul Kim},
  journal={Archives of ophthalmology},
  year={2006},
  volume={124 11},
  pages={1532-42}
}
OBJECTIVE To investigate the safety and efficacy of intravitreal ranibizumab treatment combined with verteporfin photodynamic therapy (PDT) in patients with predominantly classic choroidal neovascularization secondary to age-related macular degeneration. METHODS In this 2-year, phase I/II, multicenter, randomized, single-masked, controlled study, patients received monthly ranibizumab (0.5 mg) (n = 106) or sham (n = 56) injections. The PDT was performed 7 days before initial ranibizumab or… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 106 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Ranibi - zumab for neovascular age - related macular degeneration

  • DM Brown, PK Kaiser, M Michels
  • N Engl J Med
  • 2006

Arterial thromboembolic events ( ATEs ) in a pooled analysis of 5 randomized , controlled trials ( RCTs ) of bevacizumab ( BV ) with chemotherapy [ Abstract 3019 ]

  • Skillings, DH Johnson, K Miller
  • Avastin [ package insert ]
  • 2004

Similar Papers

Loading similar papers…